We are live on ! Find out more
RPAM

Rhenman & Partners Asset Management Portfolio holdings

AUM $810M
1-Year Est. Return 30.2%
This Fund
S&P 500
This Quarter Est. Return
-2.4%
1 Year Est. Return
+30.2%
3 Year Est. Return
+116.38%
5 Year Est. Return
+153.13%
10 Year Est. Return
+962.25%
AUM
$1.42B
AUM Growth
-$48.5M
Cap. Flow
+$49.9M
Cap. Flow %
3.5%
Top 10 Hldgs %
29.29%
Holding
97
New
3
Increased
35
Reduced
20
Closed
5

Top Buys

Rank Stock Value
1
JNJ icon
Johnson & Johnson
JNJ
+$33.3M
2
PFE icon
Pfizer
PFE
+$22.2M
3
BIIB icon
Biogen
BIIB
+$19.7M
4
APLS
Apellis Pharmaceuticals
APLS
+$14.4M
5
MCK icon
McKesson
MCK
+$14M

Top Sells

Rank Stock Value
1
XLRN
Acceleron Pharma
XLRN
+$25.6M
2
INOV
Inovalon Holdings, Inc. Class A Common Stock
INOV
+$20.4M
3
REGN icon
Regeneron Pharmaceuticals
REGN
+$14M
4
VRTX icon
Vertex Pharmaceuticals
VRTX
+$9.94M
5
PHR icon
Phreesia
PHR
+$9.11M

Sector Composition

Rank Sector Weight
1 Healthcare 96.82%
2 Industrials 1.81%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ISRG icon
26
Intuitive Surgical
ISRG
$139B
$19.9M 1.4%
60,000
-7,500
-11% -$2.52M
TDOC icon
27
Teladoc Health
TDOC
$1.29B
$19M 1.34%
150,000
-60,000
-29% -$8.74M
ALNY icon
28
Alnylam Pharmaceuticals
ALNY
$29B
$18.9M 1.33%
100,000
-35,000
-26% -$6.57M
AXNX
29
DELISTED
Axonics, Inc. Common Stock
AXNX
$18.9M 1.32%
290,000
-90,000
-24% -$6.14M
BHVN
30
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$18.8M 1.32%
135,000
-65,419
-33% -$8.17M
CNC icon
31
Centene
CNC
$32.9B
$18.7M 1.31%
300,000
+40,000
+15% +$2.67M
COO icon
32
Cooper Companies
COO
$14.9B
$18.6M 1.31%
180,000
– –
BMRN icon
33
BioMarin Pharmaceuticals
BMRN
$13.3B
$18.6M 1.3%
240,000
+80,000
+50% +$6.31M
APLS
34
DELISTED
Apellis Pharmaceuticals
APLS
$18.5M 1.3%
561,269
+256,269
+84% +$14.4M
HCA icon
35
HCA Healthcare
HCA
$89.6B
$18.2M 1.28%
75,000
– –
ZBH icon
36
Zimmer Biomet
ZBH
$18.7B
$17.6M 1.23%
123,600
-20,600
-14% -$3.03M
VEEV icon
37
Veeva Systems
VEEV
$38.1B
$17.3M 1.21%
60,000
-15,000
-20% -$4.76M
EXAS
38
DELISTED
Exact Sciences
EXAS
$17.2M 1.21%
180,000
+25,000
+16% +$2.64M
NKTR icon
39
Nektar Therapeutics
NKTR
$2.53B
$17.1M 1.2%
63,333
– –
XNCR icon
40
Xencor
XNCR
$1.6B
$16.6M 1.16%
507,002
+167,002
+49% +$5.49M
ITCI
41
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$16M 1.12%
429,728
– –
DVAX
42
DELISTED
Dynavax Technologies
DVAX
$14.4M 1.01%
750,000
– –
BDX icon
43
Becton Dickinson
BDX
$48.9B
$14.3M 1%
59,450
+10,250
+21% +$2.51M
ACCD
44
DELISTED
Accolade Inc
ACCD
$13.7M 0.96%
325,000
+25,000
+8% +$1.17M
RCM
45
DELISTED
R1 RCM Inc. Common Stock
RCM
$12.1M 0.85%
550,000
– –
HCAT icon
46
Health Catalyst
HCAT
$127M
$12M 0.84%
240,000
– –
THC icon
47
Tenet Healthcare
THC
$20.9B
$12M 0.84%
180,000
+95,000
+112% +$6.74M
EW icon
48
Edwards Lifesciences
EW
$53B
$11.9M 0.83%
105,000
-5,000
-5% -$571K
MGNX icon
49
MacroGenics
MGNX
$259M
$11.4M 0.8%
545,160
– –
NBIX icon
50
Neurocrine Biosciences
NBIX
$16.8B
$9.11M 0.64%
95,000
-10,000
-10% -$945K
1
2
3 4

Similar funds

ACM
Ashford Capital Management Wilmington, Delaware $809M AUM 35.1% 1-Year Est. Return
AR
Advisory Research Chicago, Illinois $813M AUM 36.71% 1-Year Est. Return
KCP
Kera Capital Partners San Jose, California $815M AUM 46.39% 1-Year Est. Return
BCM
Brigade Capital Management New York $806M AUM 20.71% 1-Year Est. Return
RIM
Redwood Investment Management Scottsdale, Arizona $805M AUM 15.01% 1-Year Est. Return
GCM
Glendon Capital Management Santa Monica, California $805M AUM 17.91% 1-Year Est. Return
CL
CVFG LLC Shelbyville, Indiana $804M AUM 27.61% 1-Year Est. Return
AF
Ally Financial Detroit, Michigan $804M AUM 0.18% 1-Year Est. Return

Rhenman & Partners Asset Management's Q3 2021 Portfolio in Review

As of Q3 2021, Rhenman & Partners Asset Management held 97 positions worth $1.42B, down 3.3% from $1.47B the previous quarter. Its ten largest holdings account for 29% of the portfolio.

Rhenman & Partners Asset Management deployed $49.9M of net new capital in Q3 2021, opening 3 new positions and adding to 35 existing holdings. Its largest new stake was Privia Health: 240,000 shares worth $5.65M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 95% a quarter earlier, followed by Industrials.

On the sell side, the largest reduction was Acceleron Pharma, an estimated $25.6M trimmed.

  • Rhenman & Partners Asset Management's largest Q3 2021 buy was Privia Health: 240,000 shares worth $5.65M.
  • Rhenman & Partners Asset Management added most to Johnson & Johnson in Q3 2021, an estimated $33.3M increase.
  • Rhenman & Partners Asset Management's biggest Q3 2021 reduction was Acceleron Pharma, cutting an estimated $25.6M.
  • Rhenman & Partners Asset Management fully exited Inovalon Holdings, Inc. Class A Common Stock in Q3 2021, selling an estimated $20.4M.
  • Rhenman & Partners Asset Management's ten largest holdings make up 29% of its $1.42B portfolio in Q3 2021.
  • Rhenman & Partners Asset Management opened 3 new positions and closed 5 in Q3 2021.
  • Rhenman & Partners Asset Management's portfolio value fell 3.3% quarter-over-quarter to $1.42B.

Based on Rhenman & Partners Asset Management's 13F filing for Q3 2021, filed 12 Nov 2021.